Increase in visceral adipose tissue in a woman living with HIV after introduction of integrase strand transfer inhibitor

Int J STD AIDS. 2020 Dec;31(14):1407-1410. doi: 10.1177/0956462420955075. Epub 2020 Oct 21.


Integrase strand transfer inhibitors (INSTIs) are a class of antiretroviral drugs with high virologic efficacy and excellent tolerability. Recent evidence showed a possible link of dolutegravir-based regimens with weight gain, and a relationship between raltegravir use and changes in adipose tissue density and metabolic abnormalities, with an increased cardiovascular risk, has been suggested. We describe a case where dolutegravir monotherapy led to a decrease in adipose tissue density.

Keywords: HIV; adipose tissue density; dolutegravir; integrase strand transfer inhibitor; weight gain.

Publication types

  • Case Reports

MeSH terms

  • Body Composition / drug effects*
  • Female
  • HIV Infections / drug therapy*
  • HIV Integrase Inhibitors / therapeutic use*
  • Heterocyclic Compounds, 3-Ring / therapeutic use*
  • Humans
  • Intra-Abdominal Fat
  • Middle Aged
  • Oxazines / therapeutic use*
  • Piperazines / therapeutic use*
  • Postmenopause
  • Pyridones / therapeutic use*
  • Weight Gain


  • HIV Integrase Inhibitors
  • Heterocyclic Compounds, 3-Ring
  • Oxazines
  • Piperazines
  • Pyridones
  • dolutegravir